Diadexus, Inc. Watch

from 10-Q 15 pages License and Supply Agreement Section 1. Definitions

from 10-Q 2 pages Diadexus, Inc. Non-Employee Director Compensation Policy

from 10-Q 22 pages Diadexus, Inc. Key Employee Severance Benefit Plan

from 10-Q 15 pages License and Supply Agreement Section 1. Definitions

from 10-Q 2 pages Diadexus, Inc. Non-Employee Director Compensation Policy

from 10-Q 22 pages Diadexus, Inc. Key Employee Severance Benefit Plan

from 10-Q 9 pages Diadexus, Inc. Warrant Grant Notice

from 10-Q 21 pages Diadexus, Inc. 2012 Equity Incentive Award Plan Article 1 Purpose

from 10-Q 11 pages Indemnity Agreement

from 10-Q 8 pages Agreement

from 10-Q 2 pages April 17, 2015 Lori Rafield Dear Lori: I Am Pleased to Offer You the Role of Chief Executive Officer (“CEO”) of Diadexus, Inc. (The “Company”), Effective April 17, 2015 (The “Start Date”). This Offer Letter (The “Letter”) Sets Forth the Terms of Your Employment With the Company. Role. as CEO, You Will Perform Such Duties and Responsibilities as the Board of Directors of the Company (The “Board”) May Reasonably Determine From Time to Time. Your Primary Work Location Will Be the Company’s Headquarters in South San Francisco. Base Salary. as of the Start Date, Your Initial Annual Base Salary Will Be $550,000 (The “Base Salary”), Less Applicable Payroll Deductions and Tax Withholdings, Payable on the Company’s Normal Payroll Schedule

from 10-Q 3 pages Material contract

from 8-K 12 pages Agreement

from 8-K 21 pages Diadexus, Inc. Key Employee Severance Benefit Plan

from 10-Q 2 pages Material contract

from 10-Q 4 pages Separation Agreement

from 10-Q 5 pages [ * ] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. Monday, 08 September 2014 Emi Zychlinsky, PH.D Diadexus, Inc., a Delaware Corporation 349 Oyster Point Boulevard, South San Francisco, Ca 94080-1913 Dear Emi, Re: Laboratory Services Agreement - Study Number: [ * ] – Amendment No. 2 Glaxosmithkline LLC (“Gsk”) Authorised a Contract (The “Services Agreement”) With an Effective Date of 24th April 2014 With Diadexus, Inc (“Contractor”) for the Above Referenced Study. After the Gsk Study Team’s Evaluation of [ * ] Results From Stage 1 and the Results of Study [ * ], Gsk Has Requested That Stage 2 Testing of Samples Proceed. in Addition to the Original Stage 2 Services, Gsk Requests That Additional Patient Sample Testing Work Be Performed as Follows: Request: (A) Under Stage 2, Gsk Has Requested That a Revised Total Number of Samples of [ * ] Be Tested as Described Below; · Stage 2(a) Approximately [ * ] · Stage 2(b) Approximately [ * ] · Stage 2(c) Approximately [ * ] · Stage 2(d) Approximately [ * ] · When Patient Samples Are Received by Contractor, Samples Will Be Tested Running [ * ] · the [ * ] Will Be Tested at the Contract Rate of $[ * ] (B) Ddx Had Originally Planned to Test the [ * ] and [ * ] Samples Without the Need to Aliquot Patient Samples. Gsk Have Requested That Samples Be Shipped to Ddx in the Parent Vial to Be Aliquoted at Ddx for Testing on the Same Day. in Order to Accommodate These Additional Manual Steps, Ddx Had to [ * ] Which Were Not Originally Budgeted for This Project. · Gsk Shall Reimburse Contractor for [ * ] at $[ * ] for the Duration of the Stage 2 Testing as Follows: · $[ * ] · $[ * ]

from 10-Q 2 pages Material contract

from 10-Q 6 pages Transition Agreement

from 10-Q 4 pages Exhibit B Payment/Invoicing Schedule